FNY Managed Accounts’s Vertex Pharmaceuticals VRTX Stock Holding History

FNY Managed Accounts’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,072	Closed	-$162K	–	837
2017 Q3	$162K	Buy	+1,072	New	+$161K	0.21%	72
2016 Q2	–	Sell	-3,000	Closed	-$238K	–	425
2016 Q1	$238K	Buy	+3,000	New	+$271K	0.42%	56
2015 Q3	–	Sell	-192	Closed	-$23.7K	–	582
2015 Q2	$23.7K	Buy	+192	New	+$24.2K	0.03%	218

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FNY Managed Accounts's VRTX Position: Q4 2017 in Review

FNY Managed Accounts sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 1,072 shares — an estimated $162K sold.

FNY Managed Accounts first reported a position in VRTX in Q2 2015 and held it in 3 quarters. The position peaked at $238K in Q1 2016. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

FNY Managed Accounts reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
FNY Managed Accounts sold 1,072 Vertex Pharmaceuticals shares in Q4 2017, an estimated $162K.
FNY Managed Accounts first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 3 quarters.
FNY Managed Accounts's Vertex Pharmaceuticals position peaked at $238K in Q1 2016.
644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.